Immucell (ICCC) Cash from Financing Activities (2010 - 2025)

Immucell (ICCC) has reported Cash from Financing Activities for 16 consecutive years, with -$394602.0 the latest figure, recorded in Q4 2025.

• For the quarter ending Q4 2025, Cash from Financing Activities fell 365.07% year-over-year to -$394602.0; the trailing twelve-month figure through Dec 2025 stood at -$1.2 million (down 142.06% YoY), and the FY2025 full-year result was -$1.2 million, down 142.06% from the prior year.
• Cash from Financing Activities retreated to -$394602.0 in Q4 2025 per ICCC's latest filing, from -$337689.0 in the prior quarter.
• Across five years, Cash from Financing Activities topped out at $4.0 million in Q2 2021 and bottomed at -$403647.0 in Q1 2025.
• Historically, Cash from Financing Activities has averaged $420742.0 across 5 years, with a median of -$185665.0 in 2021.
• The sharpest annual moves came in 2021 and 2022: Cash from Financing Activities tumbled 528.91% in 2021, then surged 1114.39% in 2022.
• Over 5 years, Cash from Financing Activities stood at -$194905.0 in 2021, then slipped by 27.35% to -$248209.0 in 2022, then retreated by 29.5% to -$321433.0 in 2023, then jumped by 146.31% to $148866.0 in 2024, then slumped by 365.07% to -$394602.0 in 2025.
• According to Business Quant data, Cash from Financing Activities over the past three periods registered -$394602.0, -$337689.0, and -$76448.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.